Red light therapy is drawing increasing attention as a non-invasive option for people experiencing hair thinning. But what does the clinical evidence actually show? This article summarises three peer-reviewed randomised controlled trials that examined red and near-red light for hair growth, and explains what their findings mean in practical terms.
Study 1 - Kim and colleagues (2013): Multi-Wavelength LED Helmet Trial
Study Design
This was a randomised, double-blind, sham-controlled multicenter trial conducted over 24 weeks. Participants received 18 minutes of treatment per day using a multi-wavelength LED helmet delivering light at 630nm, 650nm, and 660nm. The trial enrolled 40 subjects with androgenetic alopecia (pattern hair loss).
Key Findings
- Hair density in the treatment group increased by 17.2 hairs per cm2 compared to the sham group (p<0.05)
- Hair thickness increased by 12.6 micrometres in the treatment group vs sham (p<0.05)
- No serious adverse reactions were recorded
What This Means
Both measurable hair density and individual strand thickness improved in the active treatment group compared to the sham. The multi-wavelength approach spanning 630nm to 660nm produced statistically significant results, with a strong safety profile across all participants.
Study 2 - Lanzafame and colleagues (2014): Female Pattern Hair Loss Trial
Study Design
A double-blind randomised controlled trial focused specifically on female pattern hair loss. The device combined 21 diode lasers and 30 LEDs operating at 655nm. Of the 47 females enrolled, 42 completed the 16-week protocol.
Key Findings
- Hair count in the active treatment group increased by 100.3 hairs vs 23.9 hairs in the sham group (P<0.0001)
- Active group saw a 48.07% increase in hair count vs 11.05% in the sham group
- The research team also conducted a companion study in males (2013) showing similar results
What This Means
The difference in hair count between the active and sham groups was statistically substantial - active treatment produced more than four times the hair growth response of the sham device. The P<0.0001 significance level indicates this was not a chance finding.
Study 3 - Jimenez and colleagues (2014): Large Multicenter Trial in Males and Females
Study Design
This was a multicenter, randomised, sham-controlled, double-blind clinical trial - one of the largest published trials of its type for this application. It enrolled 269 randomised participants (128 male, 141 female), with 225 included in the efficacy analysis. The protocol ran for 26 weeks using laser devices operating at 655nm and 635nm.
Key Findings
Female groups:
- Terminal hair density increased by +20.2 to +20.6 hairs/cm2 in the active groups
- Sham groups increased by only +2.8 to +3.0 hairs/cm2 (p<0.0001)
Male groups:
- Terminal hair density increased by +18.4 to +25.7 hairs/cm2 in the active groups
- Sham groups increased by only +1.6 to +9.4 hairs/cm2 (p<0.003)
What This Means
Across both sexes, participants receiving active treatment saw substantially greater increases in terminal hair density than those using the sham device. The statistical significance held in all treatment arms, and the scale of the trial (269 enrolled participants across multiple centres) adds meaningful weight to these findings.
Why Wavelength Matters
All three studies used wavelengths between 630nm and 660nm - a range within what is commonly referred to as the therapeutic window for photobiomodulation. This range corresponds directly to the 660nm red light specification used in the Lumovex Spectrum Pro Mask.
While the devices tested in these studies were scalp-specific helmets and handheld lasers, the wavelengths involved overlap with those used in mask-format red light devices. The specific mechanism under investigation - light absorption by mitochondrial chromophores, particularly cytochrome c oxidase - is wavelength-dependent rather than device-format-dependent.
For targeted scalp sessions using a portable device, the Lumovex Portable Panel offers a compact option that delivers the same studied wavelengths at a practical size for directing at the scalp.
Summary of Findings Across All Three Studies
| Study | Wavelength(s) | Duration | Key Result | Significance |
|---|---|---|---|---|
| Kim and colleagues (2013) | 630nm, 650nm, 660nm | 24 weeks | +17.2 hairs/cm2 density; +12.6 micrometre thickness | p<0.05 |
| Lanzafame and colleagues (2014) | 655nm | 16 weeks | +100.3 hairs vs +23.9 sham (48.07% vs 11.05%) | P<0.0001 |
| Jimenez and colleagues (2014) | 655nm, 635nm | 26 weeks | +18.4 to +25.7 hairs/cm2 (male); +20.2 to +20.6 (female) | p<0.003 to <0.0001 |
Important Notes on Interpreting This Research
The studies referenced here used specific devices - scalp laser helmets and handheld laser combs - that differ from mask-format red light panels. While the wavelengths overlap, the studies do not constitute direct evidence for any specific consumer device.
Hair loss is a complex condition with multiple contributing factors. Red light therapy is one area of ongoing research and should not be considered a substitute for medical advice or treatment. If you are experiencing hair thinning, consulting a dermatologist is recommended before starting any new regimen.
Study findings reflect group averages in clinical settings. Individual results in non-clinical settings will vary.
This article is for educational purposes only and is not intended as medical advice. The studies cited are independent peer-reviewed research. Lumovex makes no claim that its products replicate the outcomes of these studies.
Leave a comment
This site is protected by hCaptcha and the hCaptcha Privacy Policy and Terms of Service apply.